2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2012
Does co-morbid depression alter the inverse relationship between obesity and substance use disorders?
Gearhardt AN, Harrison EL, McKee SA. Does co-morbid depression alter the inverse relationship between obesity and substance use disorders? Drug And Alcohol Dependence 2012, 124: 185-188. PMID: 22285319, PMCID: PMC3359394, DOI: 10.1016/j.drugalcdep.2012.01.002.Peer-Reviewed Original ResearchConceptsSubstance use disordersCo-morbid depressionDrug use disordersUse disordersRisk factorsMajor depressionOverweight/obesity statusCommon risk factorsInverse relationshipNormal weightObesity statusExcess food consumptionPsychiatric disordersDepression disorderObesityDrug useReward circuitryU.S. adultsSubstance useDisordersDepressionAdultsFood consumptionRepresentative sampleCurrent study